VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MIRM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MIRMMirum Pharmaceuticals, Inc.
$92.49$5.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMIRMCash Flow

Mirum Pharmaceuticals, Inc. (MIRM) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow swung from a $273.7M outflow in 2026Q2 to a $39.5M inflow in 2025Q3 and was -$5.6M in 2026Q3, with stock-based compensation of $33.3M in the latest quarter suggesting a meaningful portion of economic cost is paid in equity rather than cash.

Income StatementBalance SheetCash FlowRatios

MIRM Cash Flow Statement

Annual statement

MIRM Cash Flow Statement

Mirum Pharmaceuticals, Inc. (MIRM) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-500.02M55.83M10.32M-70.94M-120.14M-132.76M-89.08M-39.36M-373K
Operating CF Margin %-10.71%3.06%-38.07%-155.9%-693.69%---
Operating CF Growth %-13824.35%440.7%114.55%40.95%9.51%-49.04%-126.3%-10452.82%-
Net Income-903.88M-23.36M-87.94M-163.41M-135.66M-83.99M-103.27M-52.55M-17.35M
Depreciation & Amortization26.77M24.24M23.63M10.83M3.24M975K623K324K4.37M
Stock-Based Compensation155.31M71.42M48.44M35.02M27.01M23.09M12.55M6.07M51K
Deferred Taxes0000-6.58M595K72K00
Other Non-Cash Items850.74M3.24M3.6M69.26M12.91M-90.41M335K-326K10.11M
Working Capital Changes161.18M-19.71M22.59M-22.64M-21.05M16.98M611K7.12M2.44M
Change in Receivables-71.58M-48.05M-11.43M-43.97M-20.73M0000
Change in Inventory-6.62M-8.45M-3.17M-4.39M-3.45M-495K000
Change in Payables128.06M50.1M40.31M30.78M7.64M22.66M3.68M10.06M2.45M
Cash from Investing-210.99M-23.95M-90.13M-107.2M7.7M48.55M37.87M-127.78M-7.5M
Capital Expenditures-13.26M-954K-993K-109K-278K-19.02M-225K-281K-7.5M
CapEx % of Revenue1.98%0.18%0.29%0.06%0.36%99.4%---
Acquisitions000-212.76M-7.98M-19M-38.1M127.5M0
Investments---------
Other Investing-35M0-20M-20M7.98M127M38.1M-127.5M-11.25M
Cash from Financing706.25M40.14M17.7M336.6M109.09M73.47M181.29M127.18M59.84M
Debt Issued (Net)135.97M00305.3M000050K
Equity Issued (Net)570.29M40.14M17.7M216.68M107.37M6.91M131.87M127.18M59.79M
Dividends Paid000000000
Share Repurchases000000000
Other Financing000-185.39M1.72M66.55M49.42M00
Net Change in Cash-9.35M75.24M-63.4M158.32M-3.34M-10.75M130.12M-39.99M51.96M
Free Cash Flow-503.28M54.87M9.33M-91.05M-120.41M-151.78M-89.3M-39.64M-7.87M
FCF Margin %-75.03%10.53%2.77%-48.85%-156.26%-793.09%---
FCF Growth %-1235.61%488.01%110.25%24.38%20.67%-69.97%-125.26%-403.53%-
FCF per Share-7.621.090.20-2.23-3.54-5.01-3.54-1.72-0.34
FCF Conversion (FCF/Net Income)0.56x-2.39x-0.12x0.43x0.89x1.58x0.86x0.75x0.02x
Interest Paid300K012.65M6.82M00000
Taxes Paid2.15M01M125K0011K21K0

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Cash burn from operations

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Losses Overshadow Operating Cash Swings

Based on the reported quarterly figures, MIRM's operating cash flow swung from a $273.0M outflow in 2026Q2 to a $6.1M inflow in 2025Q4, while net income remained negative in most quarters, making the conversion ratio unreliable for judging earnings quality. The mismatch between the two suggests working capital timing, not earnings, is driving cash results.

The 2026Q1 net loss of $790.2M sits against an operating cash outflow of only $228.8M, which points to a large non-cash or one-time charge rather than operating deterioration. Conversion ratios such as OCF/NI of 4.06 in 2026Q2 are mathematically meaningful only because both figures are negative, so they should not be read as evidence of cash generation. Investors should monitor whether the reported cash outflows reflect a sustained operating burn or episodic working capital movements.

Free Cash Flow Remains Deeply Volatile

According to the reported quarterly data, MIRM's free cash flow margin ranged from -155.3% in 2026Q2 to 29.7% in 2025Q3, with the company generating positive FCF in only three of the last ten quarters. This pattern indicates cash generation has not yet stabilized into a durable trend.

The sharp move to a $273.7M FCF outflow in 2026Q2, following a brief positive quarter in 2025Q3, suggests the business is still exposed to large swings in working capital and collections. Positive FCF quarters in 2025 were small in absolute terms relative to the $185.7M quarterly revenue base, so profitability has not yet translated into consistent cash surplus. The trajectory warrants further investigation before a sustainable cash profile can be assumed.

Working Capital Drives Quarterly Cash Volatility

As reported in the financial statements, MIRM's working capital change reached $102.2M in 2026Q1 and $62.0M in 2026Q2, while several 2025 quarters showed reversals of similar magnitude, indicating receivables and payables timing dominates reported cash results.

Large working capital swings relative to operating losses suggest the cash figures are more sensitive to collection and payment timing than to underlying unit economics. The repeated sign reversals imply that quarterly OCF is poorly representative of run-rate cash generation. Investors may wish to examine receivables aging and payables terms to determine whether these movements are structural or temporary.

Minimal Capital Intensity Limits Investment Drag

Based on MIRM's reported figures, capital expenditure remained below 1% of revenue in most quarters, with the exception of a 6.7% ratio in 2026Q1 when CapEx reached $10.7M, indicating the business is asset-light.

The low capital intensity means that cash burn is driven almost entirely by operating expenses and working capital rather than by investment in physical assets. The single elevated CapEx quarter in 2026Q1 appears isolated and does not establish a trend in asset investment. Because D&A runs near $6.1M per quarter, maintenance requirements appear modest relative to the reported revenue base.

Stock-Based Compensation Masks Cash Dilution

According to the reported figures, MIRM's stock-based compensation reached $66.8M in 2026Q2 and has exceeded $13M in most recent quarters, meaning a meaningful share of economic cost is paid in equity rather than cash and may flatter the cash outflow picture.

Because SBC is added back in operating cash flow, the reported cash burn understates the full economic cost borne by shareholders through dilution. The elevated SBC relative to operating cash outflows suggests that equity issuance may be substituting for cash compensation. Investors should weigh reported FCF alongside share count growth to gauge the true cost of the operating model.

MIRM — Frequently Asked Questions

Quick answers to the most common questions about buying MIRM stock.

How much cash does Mirum Pharmaceuticals, Inc. (MIRM) generate from operations?

Mirum Pharmaceuticals, Inc. (MIRM) generated $55.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Mirum Pharmaceuticals, Inc.'s free cash flow?

Mirum Pharmaceuticals, Inc. (MIRM) generated $54.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Mirum Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Mirum Pharmaceuticals, Inc. (MIRM) spent $1.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.